Merck & Co., Inc. (NYSE:MRK) Releases Earnings Results

Merck & Co., Inc. (NYSE:MRK) Releases Earnings Results

Merck & Co., Inc. (NYSE:MRK - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. During the same quarter last year, the busi…

Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction

Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch.

Merck outlines 2026 revenue of $66.8B-$67.3B and EPS of $2.77-$2.82 while investing ahead of KEYTRUDA LOE (NYSE:MRK)

Merck Q3 2026 earnings: revenue rose 5%, guidance increased, and pipeline momentum built despite 2027 headwinds.

Merck & Co., Inc. (MRK) Stock: Jumps 3.84% as Q3 2026 Revenue Rises 5% to $18.1 Billion

TLDR MRK Stock Jumps 3.84% as Merck Reports $18.1 Billion in Q3 2026 Revenue Growth Merck Stock Rises as KEYTRUDA Sales Hit $8.6 Billion and WINREVAIR Jumps 93% MRK Stock Climbs After Merck Raises 2026 Sales Forecast to 66.8B–67.3 Billion Merck Q3 Earnings Reveal 5% Revenue Growth Despite Declining Quarterly EPS in 2026 MRK Stock [...]

Merck raises outlook after US$18.1B third quarter

Merck reported quarterly sales of US$18.1 billion and adjusted earnings of US$2.49 a share, while raising its full-year sales forecast midpoint.